PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-62.27%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
43.14%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.75%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.75%
Both companies reducing total costs. Martin Whitman would check industry trends.
-100.00%
Interest expense reduction while AGEN shows 4.12% growth. Joel Greenblatt would examine advantage.
975.86%
D&A growth above 1.5x AGEN's 1.48%. Michael Burry would check for excessive investment.
-265.35%
EBITDA decline while AGEN shows 8.82% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
7.75%
Similar operating income growth to AGEN's 8.63%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
-2437.42%
Other expenses reduction while AGEN shows 189.40% growth. Joel Greenblatt would examine advantage.
-313.81%
Pre-tax income decline while AGEN shows 21.07% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing tax expense. Martin Whitman would check patterns.
-313.81%
Net income decline while AGEN shows 21.07% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-286.19%
EPS decline while AGEN shows 32.78% growth. Joel Greenblatt would examine position.
-286.19%
Diluted EPS decline while AGEN shows 32.78% growth. Joel Greenblatt would examine position.
6.89%
Share count reduction exceeding 1.5x AGEN's 17.57%. David Dodd would verify capital allocation.
6.89%
Diluted share reduction exceeding 1.5x AGEN's 17.57%. David Dodd would verify capital allocation.